Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
Los Angeles Times (LT) - SATURDAY September 16, 1989 Edition: Home Edition Section: Metro Page: 8 Pt. 2 Col. 1 Story Type: Editorial Word Count: 574
The cost implications of the discovery are enormous, however. The nation was hard-pressed to meet the cost of AZT for AIDS patients. California, the only state with a substantial AZT program funded from state revenues, is a case in point. The California program is now providing AZT to about 1,400 persons a month. The state's AZT budget is $2.5 million this year. But the total infected population in California may be as high as 250,000 persons, and even if only 40% of that group qualified for state-supported treatment, and even calculating the treatment at lower dosages, that would indicate a cost of $300 million a year.
At the federal level, there are no precise cost estimates of extending AZT to asymptomatic persons with HIV infection, but experts have spoken of an annual cost of $2.5 billion to cover basic treatments, including aerosol pentamidine, AZT and the immune system tests required to monitor the treatment program for the infected population. The $20-million increase in federal funding approved by the Senate Appropriations Committee only brings the level of federal funding to $30 million, the level where it was in 1987.
Formal approval of the use of AZT for asymptomatic HIV-infected persons by the Food and Drug Administration is required. When that formality is completed, there will be greatly increased demand for subsidized treatment as well as for coverage by private insurance plans that include prescription drugs. But it is by no means clear where the vast sums of money will be found.
The new research has again focused attention on the extraordinarily high cost of AZT. The manufacturer, Burroughs Wellcome, has made one 20% cut in the price since it was put into general use in March of 1987. The drug now sells wholesale at $1.50 a capsule. The standard prescription is 12 a day at a retail cost of about $8,000 a year. The reduced dosage of five a day, used effectively in the treatment of asymptomatic persons, would cost more than $3,000 a year at retail. Burroughs Wellcome has defended its pricing as essential to funding its continuing research program. But it has drawn sharp criticism, not least because a substantial part of the original research on the basic drug and its clinical testing were funded by the federal government. Pressure for a major price cut is growing, quite understandably.
There is, at this time, no equal to AZT in prolonging the lives of those with HIV infection. An experimental drug, DDI, is going into free distribution pending formal approval as a substitute for those who cannot tolerate AZT, while Bristol-Myers Co., the manufacturer of DDI, has yet to indicate what the price will be when it is finally approved. Neither AZT nor DDI is a cure. The sheer cost of AZT means that, without government subsidy, it is beyond the reach of millions of infected persons. Its extraordinary usefulness in extending lives has created a challenge to public health in the United States that cannot be ignored.
890916
LT890908
Copyright © 1989 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .